Download PDF
Thromb Haemost 1998; 79(02): 264-267
DOI: 10.1055/s-0037-1614976
Letters to the Editor
Schattauer GmbH

Rapid Haemodynamic Improvement Following Saruplase in Recent Massive Pulmonary Embolism

Gérard Pacouret
1   From Cardiologie D Department, Trousseau Hospital, Tours, France
,
Sarah J. Barnes
2   From Gruenenthal GmbH, Aachen, Germany
,
Gwyn Hopkins
2   From Gruenenthal GmbH, Aachen, Germany
,
Bernard Charbonnier
1   From Cardiologie D Department, Trousseau Hospital, Tours, France
› Author Affiliations
Further Information

Publication History

Received 24 March 1997

Accepted after resubmission 12 September 1997

Publication Date:
08 December 2017 (online)

Also available at
    Permissions and Reprints

Summary

In a single centre pilot study, saruplase (20 mg bolus plus 60 mg infusion over 1 h) was administered to twenty patients with an angio-graphically documented recent massive pulmonary embolism: Miller index of at least 20 and mean pulmonary artery pressure of at least 20 mmHg. The lytic ability of saruplase to cause normalization of haemodynamic parameters over the first 12 h and reperfusion of pulmonary arteries at 24 h was assessed. A decrease of 25 ± 10% in total pul monary resistance was evident at 30 min. Haemodynamic parameters continued to improve with total pulmonary resistance decreasing by 29 ± 8% and 40 ± 11% at 1 and 12 h respectively. Relative improve ment in Miller index 24 ± 6 h after saruplase treatment was 38 ± 9%. Two patients suffered recurrent pulmonary embolism, two severe bleeding events were observed. One patient died following a haemorrhagic stroke.

 

  • References

  • 1 Meyer G, Charbonnier B, Stern M, Brochier ML, Sors H. Thrombolysis in acute pulmonary embolism. In: Thrombolysis in Cardiovascular Disease. Julian D, Kübler W, Norris RM, Swan HJC, Collen D, Verstraete M. eds. Basel, New York: Marcel Dekker Company; 1989: 337-60.
    Search in Google Scholar
  • 2 Petitpretz P, Simonneau G, Cerrina J, Musset D, Dreyfus M, Vandenbroek MD, Duroux P. Effects of a single bolus of Urokinase in patients with life-threatening pulmonary emboli: a descriptive trial. Circulation 1984; 70: 861-6.
    CrossrefPubMedSearch in Google Scholar
  • 3 Meyer G, Sors H, Charbonnier B, Kasper W, Bassand JP, Kerr IH, Lesaffre E, Vanhove P, Verstraete M. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicentre double-blind trial. J Am Coll Cardiol 1992; 19: 239-45.
    CrossrefPubMedSearch in Google Scholar
  • 4 Sors H, Pacouret G, Azarian R, Meyer G, Charbonnier B, Simonneau G. Hemodynamic effects of bolus versus 2 h infusion of alteplase in acute massive pulmonary embolism. A randomized controlled multicenter trial. Chest 1994; 106: 712-7.
    CrossrefPubMedSearch in Google Scholar
  • 5 PRIMI Trial Study Group.. Randomised double-blind trial of recombinant pro-urokinase against streptokinase in acute myocardial infarction. Lancet 1989; 1: 863-8.
    PubMedSearch in Google Scholar
  • 6 Meneveau N, Bassand JP, Schiele F, Boura Y, Anguenot T, Bernrd Y, Schultz R. Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with non elderly patients. J Am Coll Cardiol 1993; 2: 1075-9.
    PubMedSearch in Google Scholar
  • 7 Flohé L. Recombinant human pro-urokinase (non-glycosylated). Drugs Future 1986; 11: 851-2.
    CrossrefPubMedSearch in Google Scholar
  • 8 Miller GAH, Sutton GS, Kerr IH, Gibson RV, Honey M. Comparison of streptokinase and heparin in treatment of isolated massive pulmonary embolism. Br Med J 1971; 2: 681-4.
    CrossrefPubMedSearch in Google Scholar
  • 9 Brochier M, Raynaud P, Fauchier JP, Charbonnier B, Latour F, Alison A, Pellois A, Planiol T. Comparison between lung scans and pulmonary angio-grams in the evaluation of the perfusion defect in massive and submassive pulmonary embolism. Prog Resp Res (Karger, Basel) 1980; 13: 120-6.
    PubMedSearch in Google Scholar
  • 10 Vermeer F, Bär FW, Windeler J, Schenkel W. Saruplase: a new fibrin spe cific thrombolytic agent. Final results of the PASS study (1698 patients). Circulation 1993; 88: I.292.
    PubMedSearch in Google Scholar
  • 11 Diehl JL, Meyer G, Igual J, Collignon AMA, Giselbrecht M, Even P, Sors H. Effectiveness and safety of bolus administration of alteplase in massive pulmonary embolism. Am J Cardiol 1992; 70: 1477-80.
    CrossrefPubMedSearch in Google Scholar
  • 12 Levine M, Hirsh J, Weitz J, Cruickshank M, Neemeh J, Turpie AG, Gent M. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98: 1473-9.
    CrossrefPubMedSearch in Google Scholar